Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

InflammaGen™ Therapeutics to Present Case Review of InflammaGen Shok-Pak at BIO-Europe 2011


News provided by

InflammaGen Therapeutics

31 Oct, 2011, 13:33 GMT

Share this article

Share toX

Share this article

Share toX

SAN DIEGO and DUSSELDORF, Germany, October 31, 2011 /PRNewswire/ --

- Presentation to Highlight Patient Experience and Recovery from Multiple Organ Failure

- Phase 2 Pilot Study Expected to Commence by Year End 2011

InflammaGen™ Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF), announced today that the Company will present a case review during BIO-Europe 2011 detailing the first-ever in-human experience involving InflammaGen Shok-Pak.  The case review will be presented by Hank Loy, president of InflammaGen Therapeutics, on Tuesday, November 1 at 11:00 a.m., CET (6:00 a.m., ET) on Level 2, Room 26 at the CCD Conference Center in Dusseldorf, Germany. 

InflammaGen Shok-Pak is a drug/delivery technology designed to prevent the onset of shock and MOF via the direct administration of an enzyme inhibitor into the stomach and lumen of the intestine.  A Phase 2 pilot study of the InflammaGen Shok-Pak is expected to begin by year end 2011.

John Rodenrys, CEO of InflammaGen Therapeutics, commented, "We welcome the opportunity to present this case review at BIO-Europe 2011 to showcase the value of InflammaGen Shok-Pak as a potential treatment for shock and MOF.  Our pre-clinical research and patient experiences have demonstrated that blocking the release of digestive enzymes from the intestine to the bloodstream appears to play a critical role in treating and reversing shock and MOF, thereby enabling those inflicted with the condition to recover and survive.  We look forward to continuing the clinical development of this unique technology with the initiation of a Phase 2 pilot study."

The case review at BIO-Europe 2011 highlights the recovery of a 58 year-old male patient and prior cardiac transplant survivor who was treated with InflammaGen Shok-Pak after being diagnosed with Fournier's gangrene and acute septic shock.  The patient was the first human treated with InflammaGen Shok-Pak, which has now been used outside the U.S. as a rescue therapy for 13 patients, all of whom were diagnosed with life-threatening conditions.  In addition to the successful ex-U.S. human experiences, pre-clinical studies of InflammaGen Shok-Pak in two animal species have demonstrated significant increases in long-term survival.

Mr. Loy remarked, "Despite the prevalence and severity of MOF, current therapies to treat this potentially grave condition are limited both in availability and effectiveness.  Our therapeutic and diagnostic platform is being developed to address this severe medical need, and we believe it may eventually offer a significant breakthrough in the survivability of shock and MOF patients."

InflammaGen Shok-Pak was developed based on research from the University of California, San Diego.  Dr. Geert Schmid-Schonbein, lead investigator, and colleagues discovered that under conditions of shock, the epithelial cell barrier in the small intestine becomes permeable causing highly potent digestive enzymes to be carried into the bloodstream and lymphatic system where they can lead to MOF and death.  Dr. Schmid-Schonbein and his colleagues demonstrated that by delivering an enzyme inhibitor directly into the lumen of the intestine via a nasogastric tube they could block the digestive enzymes, thereby inhibiting the progression from acute shock to MOF. Dr. Schmid-Schonbein was awarded the 2008 Landis Award for this discovery, termed Autodigestion.

InflammaGen Therapeutics is also developing a tandem diagnostic, AnaZyme, which is designed to detect the onset and severity of shock from either breath or blood samples.  AnaZyme is intended to be used in critical care situations to enable first responders, nurses and physicians to identify the signs of shock before it cascades to MOF, enabling healthcare workers to quickly administer InflammaGen therapy following the technologies' approval by the FDA and other regulatory agencies.

About Multiple Organ Failure

Multiple Organ Failure (MOF) is a potentially life-threatening disturbance in normal organ function caused by acute shock (trauma, sepsis, burn, SIRS, etc).  Without swift medical intervention, the patient's organs will progressively continue to fail, decreasing one's chances of survival.  In the United States, shock is the second leading cause of in-hospital deaths, with approximately 750,000 cases occurring annually.(1) It is estimated that between 28 and 50 percent of these patients die, exceeding the number of of U.S. deaths from prostate cancer, breast cancer and AIDS combined.(2)  In 2007, sepsis accounted for an estimated $38 billion in hospital billings.

  1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Critical Care Medicine. 2001 Jul;29(7):1303-10
  2. Wood KA, Angus DC. Pharmacoeconomic implications of new therapies in sepsis. PharmacoEconomics. 2004;22(14):895-906. 

About InflammaGen™ Therapeutics

InflammaGen Therapeutics is a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF), a condition with a high mortality rate and very few therapeutic options.  The Company's lead technology is InflammaGen Shok-Pak, a drug/delivery platform designed to prevent the onset of shock and MOF via the direct administration of an enzyme inhibitor into the stomach and lumen of the intestine. InflammaGen Shok-Pak was developed based on research from the University of California San Diego, which demonstrated that under conditions of shock, digestive enzymes permeate the wall of the intestine and enter the bloodstream, leading to multi-organ failure and death.  Complementing InflammaGen Shok-Pak, the Company has also developed a diagnostic assay -- AnaZyme -- that uses either breath or blood samples to measure the presence and severity of inflammatory activity due to shock, and InflammaGen Lavage, a therapeutic for use in open wounds and areas of infection.  InflammaGen Therapeutics is a Leading Biosciences' company.  For additional information on Leading Biosciences, please visit http://leadingbiosciences.com/. For additional information on InflammaGen Therapeutics or its MOF treatment platform, please visit http://igenrx.com/. 

Contact Information:
Hank Loy
President
InflammaGen Therapeutics
+1-949-939-6005
hank.loy@igenrx.com


Media Contacts:
Tiberend Strategic Advisors, Inc.
+1-212-827-0020
Jason Rando / Stephanie Denis
jrando@tiberend.com / sdenis@tiberend.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.